IMT 504

Drug Profile

IMT 504

Alternative Names: IMT504

Latest Information Update: 05 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immunotech SA
  • Class Oligodeoxyribonucleotides
  • Mechanism of Action B cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Hepatitis B; Influenza virus infections; Neuropathic pain; Osteoporosis; Rabies; Sepsis

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Diabetes mellitus in Argentina (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Diabetes mellitus presented at the the 99th Annual Meeting of the Endocrine Society (ENDO 2017)
  • 10 Jul 2008 IMT 504 is available for licensing (http://www.immunotech-sa.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top